The recent development of sensitive plasma assays for p-tau and NfL applied across the clinical AD continuum provides additional support for the early, initiating role of Aβ in AD pathogenesis and will further facilitate the use of fluid biomarkers in clinical trials [46–48]. This evidence concerns the gene NEFL and Alzheimer disease.